|
|
|
|
| | | | USD | EUR | GBP | JPY | 83.44 | 89.46 | 104.56 | 0.53 |
| | | | AED | AUD | CHF | CAD | 17.54 | 49.53 | 64.49 | 50.06 |
| | | | HKD | SAR | SGD | ZAR | 8.28 | 17.22 | 47.46 | 4.57 |
|
|
|
|
|
|
|
|
|
|
|
Industry :
|
Pharmaceuticals & Drugs
|
|
|
|
|
|
|
|
|
|
52-Week-High (Rs.)
|
1177.00
|
|
|
|
|
|
|
* BSE PRICES
|
|
|
|
|
|
( Rs. in Million)
|
Particulars | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Profit Before Tax | 16,143.50 | 16,374.80 | 41,930.10 | 23,700.50 | 19,646.20 | Adjustment | 1,751.90 | -306.50 | 531.50 | 4,142.00 | 4,589.90 | Changes In working Capital | 3,322.10 | 28,119.50 | -6,247.80 | -2,041.80 | -14,116.00 | Cash Flow after changes in Working Capital | 21,217.50 | 44,187.80 | 36,213.80 | 25,800.70 | 10,120.10 | Cash Flow from Operating Activities | 18,211.60 | 37,267.10 | 29,945.30 | 22,013.80 | 5,298.90 | Cash Flow from Investing Activities | -34,596.80 | -16,135.10 | -26,487.30 | -9,516.80 | -12,973.60 | Cash Flow from Financing Activities | 17,194.80 | -24,475.40 | -280.60 | -12,546.50 | 5,994.00 | Net Cash Inflow / Outflow | 809.60 | -3,343.40 | 3,177.40 | -49.50 | -1,680.70 | Opening Cash & Cash Equivalents | 482.10 | 3,835.80 | 673.50 | 687.00 | 2,399.50 | Cash & Cash Equivalent on Amalgamation / Take over / Merger | 0 | 0 | 0 | 6.30 | 0 | Cash & Cash Equivalent of Subsidiaries under liquidations | 0 | 0 | 0 | 0 | 0 | Translation adjustment on reserves / op cash balalces frgn subsidiaries | 0 | 0 | 0 | 0 | 0 | Effect of Foreign Exchange Fluctuations | 4.80 | -10.30 | -15.10 | 29.70 | -31.80 | Closing Cash & Cash Equivalent | 1,296.50 | 482.10 | 3,835.80 | 673.50 | 687.00 |
|
|
|
|
|
|